|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
Signal Strength: MEDIUM
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.
Ra Pharmaceuticals Inc (NASDAQ:RARX) current pivot point is: $ 47.027.
The current resistance levels are:
The current support levels are:
Pivots Points are significant levels chartists can use to determine directional movement support and resistance. Pivot Points use the prior period’s high low and close to formulate future support and resistance. In this regard Pivot Points are predictive or leading indicators.
Calculation: Pivot Points:
1) Pivot Point (P) = (High + Low + Close)/3;
2) Support 1 (S1) = (P x 2) – High; Support 2 (S2) = P - (High - Low);
3) Resistance 1 (R1) = (P x 2) – Low Resistance 2; (R2) = P + (High - Low);
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|IIIN Insteel Industries||26.01||6.9||349,900||-0.11||BEARISH CROSSOVER|
|NNBR Nn Inc||9.97||4.6||339,800||-0.29||BEARISH CROSSOVER|
|QCOM Qualcomm Inc||95.91||4.5||23,694,300||-1.13||BEARISH CROSSOVER|
|ATRC Atricure Inc||38.25||4.1||790,500||-0.02||BEARISH CROSSOVER|
|ELGX Endologix Inc||2.03||3.6||273,500||-0.01||BEARISH CROSSOVER|
|RUN Sunrun Inc||17.18||3.5||3,455,500||-0.18||BEARISH CROSSOVER|
|GBLI Global Indemnity Plc||30.7||3.2||13,100||-0.37||BEARISH CROSSOVER|
|PETS Petmed Express Inc||27.26||2.8||905,900||-0.19||BEARISH CROSSOVER|
|BCOM B Communications||1.61||2.5||700||-0.06||BEARISH CROSSOVER|
|MTSC MTS Systems||51.67||2.2||113,400||-0.07||BEARISH CROSSOVER|